Telomerase, immortality and cancer

Biotechnology Annual Review

Volumn 6, Issue , 2000, Pages 103-140

  Krupp, Guido ^a   Bonatz, Gabriele ^a   Parwaresch, Reza ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Endometrioid cancer; Endometrium; Ki 67; Lobster; Monoclonal antibody; Proliferation markers; Rainbow trout; Repp 86; Telomerase inhibitors; Tumor prognostics

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KI 67; RNA; TELOMERASE; TELOMERASE INHIBITOR;

CANCER; CANCER THERAPY; CARCINOGENESIS; CELL AGING; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSPLANTATION; CHROMOSOME; CRUSTACEA; EMBRYONAL TISSUE; ENZYME ACTIVITY; EUKARYOTIC CELL; FISH; GENOME; GERM CELL; HUMAN; MAMMAL; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TELOMERE; TISSUE REGENERATION; TUMOR CELL; TUMOR DIAGNOSIS; ANIMAL; BIOLOGICAL MODEL; CELL DIVISION; CELL TRANSFORMATION; METABOLISM; NEOPLASM; SPECIES DIFFERENCE;

EUKARYOTA; MAMMALIA; ONCORHYNCHUS MYKISS;

ANIMALS; CELL AGING; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MODELS, GENETIC; NEOPLASMS; SPECIES SPECIFICITY; TELOMERASE; TELOMERE;

EID: 0034568579     PISSN: 13872656     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1387-2656(00)06020-8     Document Type: Article

References (224)

1. Kornberg A, Baker TA. DNA Replication. Freeman and Company, New York, 1992.
2. Weiner AM. Eukaryotic nuclear telomeres: molecular fossils of the RNP world? Cell 1988; 52: 155-157.
3. Weiner AM, Maizels N. tRNA-like structures tag the 3' ends of genomic RNA molecules for replication: implications for the origin of protein synthesis. Proc Natl Acad Sci USA 1987; 84: 7383-7387.
4. Olovnikov AM. [Principle of marginotomy in template synthesis of polynucleotides]. Dokl Acad Nauk SSSR 1971; 201: 1496-1499.
5. Olovnikov AM. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J theor Biol 1973; 41: 181-190.
6. Watson JD. Origin of concatemeric T7 DNA. Nature New Biol 1972; 239: 197-201.
7. Blackburn EH, Gall JG. A tandemly repeated sequence at the termini of the extrachromosomal ribosomal RNA genes in Tetrahymena. J Mol Biol 1978; 120: 33-53.
8. Shampay J, Szostak JW, Blackburn EH. DNA sequences of telomeres maintained in yeast. Nature 1984; 310: 154-160.
9. Meyne J, Ratliff RL, Moyzis RK. Conservation of the human telomere sequence (TTAGGG)n among vertebrates. Proc Natl Acad Sci USA 1989; 86: 7049-7053.
10. Richards EJ, Ausubel FM. Isolation of a higher eukaryotic telomere from Arabidopsis thaliana. Cell 1988; 53: 127-136.
11. Okazaki S, Tsuchida K, Maekawa H, Ishikawa H, Fujiwara H. Identification of a pentanucleotide telomeric sequence, (TTAGG)n, in the silkworm Bombyx mori and in other insects. Mol Cell Biol 1993; 13: 1424-1432.
12. Klapper W, Khne K, Singh KK, Heidorn K, Parwaresch R, Krupp G. Longevity of lobsters is linked to ubiquitous telomerase expression. FEBS Lett 1998; 439: 143-146.
13. Wellinger RJ, Wolf AJ, Zakian VA. Saccharomyces telomeres acquire single-strand TG1-3 tails late in S phase. Cell 1993; 72: 51-60.
14. Wellinger RJ, Ethier K, Labrecque P, Zakian VA. Evidence for a new step in telomere maintenaince. Cell 1996; 85: 423-433.
15. Makarov VL, Hirose Y, Langmore JP. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell 1997; 88: 657-666.
16. Henderson E, Hardin CC, Walk SK, Blackburn EH. Telomeric DNA oligonucleotides form novel intramolecular structures containing guanine:guanine base pairs. Cell 1987; 51: 899-908.
17. Rothstein RJ. One-step gene disruption in yeast. Meth Enzymol 1983; 101: 202-211.
18. Muller HJ. The remaking of chromosomes. The Collecting Net 1938; 13: 181-198.
19. Zahler AM, Williamson JR, Cech TR, Prescott DM. Inhibition of telomerase by G-quartet DNA structures. Nature 1991; 350: 718-720.
20. LaBranche H, Dupuis S, Ben-David Y, Bani RM, Wellinger RJ, Chabot B. Telomere elongation by hnRNP A1 and a derivative that interacts with telomeric repeats and telomerase. Nature Genetics 1998; 19: 199-202.
21. Bianchi A, Smith S, Chong L, Elias P, de Lange T. TRF1 is a dimer and bends telomeric DNA. EMBO J 1997; 16: 1785-1794.
22. Broccoli D, Smogorzewska A, Chong L, de Lange T. Human telomeres contain two distinct MYb-related proteins, TRF1 and TRF2. Nature Genetics 1997; 17: 231-235.
23. Smith S, Giriat I, Schmitt A, de Lange T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 1998; 282: 1484-1487.
24. van Steensel B, de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature 1997;385:740-743.
25. van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998; 92: 401-413.
26. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, de Lange T. Mammalian telomeres end in a large duplex loop. Cell 1999; 97: 503-14.
27. Biessmann H, Carter SB, Mason JM. Chromosome ends in Drosophila without telomeric DNA sequences. Proc Natl Acad Sci USA 1990; 87: 1758-1761.
28. Zhang YJ, Kamnert I, Lopez CC, Cohn M, Edstrom JE. A family of complex tandem DNA repeats in the telomeres of Chironomus pallidivittatus. Mol Cell Biol 1994; 14: 8028-8036.
29. Pardue ML, DeBaryshe PG. Telomeres and telomerase: more than the end of the line. Chromosoma 1999; 108: 73-82.
30. Blackburn EH, Greider CW. Telomeres. CSHL Press, Cold Spring Harbor, 1995.
31. Oka Y, Shiota S, Nakai S, Nishida Y, Okubo S. Inverted terminal repeat sequence in the macronuclear DNA of Stylonichia pustulata. Gene 1980; 10: 301-306.
32. Klobutcher LA, Swanton MT, Donini P, Prescott DM. All gene-sized DNA molecules in four species of hypotrichs have the same terminal sequence and an unusual 3'-terminus. Proc Natl Acad Sci USA 1981; 78: 3015-3019.
33. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985; 43: 405-413.
34. Greider CW, Blackburn EH. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 1989; 337: 331-337.
35. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J, Le S, West MD, Harley CB, Andrews WH, Greider CW, Villeponteau B. The RNA component of human telomerase. Science 1995; 269: 1236-1241.
36. Collins K, Kobayashi R, Greider CW. Purification of Tetrahymena telomerase and cloning of genes encoding the two protein components of the enzyme. Cell 1995; 81: 677-686.
37. Nakayama J, Saito M, Nakamura H, Ishikawa F. TLP1: a gene encoding a protein component of mammalian telomerase is a novel member of WD reapeats family. Cell 1997; 88: 875-884.
38. Harrington LA, McPhail T, Mar V, Zhou W, Oulton R, Amgen EST Program, Arruda I, Robinson MO. A mammalian telomerase associated protein. Science 1997; 275: 973-977.
39. Lingner J, Cech TR. Purification of telomerase from Euplotes aediculatus: requirement of a primer 3' overhang. Proc Natl Acad Sci USA 1996; 93: 10712-10717.
40. Lingner J, Hughes TR, Shevchenko A, Mann M, Lundblad V, Cech TR. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 1997; 276: 561-567.
41. Harrington L, Zhou W, McPhail T, Oulton R, Yeung DSK, Mar V, Bass MB, Robinson MO. Human telomerase contains evolutionary conserved catalytic and structural subunits. Genes & Dev 1997; 11: 3109-3115.
42. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997;90:785-795.
43. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997; 277: 955-959.
44. Kilian A, Bowtell DD, Abud HE, Hime GR, Venter DJ, Keese PK, Duncan EL, Reddel RR, Jefferson RA. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet 1997; 6: 2011-2019.
45. Collins K, Gandhi L. The reverse transcriptase component of the Tetrahymena telomerase ribonucleoprotein complex. Proc Natl Acad Sci USA 1998; 95: 8485-8490.
46. Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE, Bodnar AG, Lichtsteiner S, Kim NW, Trager JB, Taylor RD, Carlos R, Andrews WH, Wright WE, Shay JW, Harley CB, Morin GB. Reconstitution of human telomerase with the template RNA component hTR and the catalytic subunit hTRT. Nature Genetics 1997; 17: 498-502.
47. Beattie TL, Zhou W, Robinson MO, Harrington L. Reconstitution of human telomerase activity in vitro. Curr Biol 1998; 8: 177-180.
48. Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 1989; 59: 521-529.
49. Counter CM, Hirte HW, Bacchetti S, Harley CB. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA 1994; 91: 2900-2904.
50. Nilsson P, Mehle C, Remes K, Roos G. Telomerase activity in vivo in human malignant hematopoietic cells. Oncogene 1994; 9: 3043-3048.
51. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
52. Morin GB. Recognition of a chromosome truncation site associated with alpha-thalassaemia by human telomerase. Nature 1991; 353: 454-456.
53. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990; 346: 866-868.
54. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990; 345: 458-460.
55. Cooke HJ, Smith BA Variability at the telomeres of the human X/Y pseudoautosomal region. Cold Spring Harbor Symp. Quant Biol 1986; 51: 213-219.
56. Allshire RC, Gosden JR, Cross SH, Cranston G, Rout D, Sugawara N, Szostak JW, Fantes PA, Hastie ND. Telomeric repeat from T. thermophila cross hybridizes with human telomeres. Nature 1988; 332: 656-659.
57. de Lange T, Shiue L, Myers RM, Cox DR, Naylor SL, Killery AM, Varmus HE. Structure and variability of human chromosome ends. Mol Cell Biol 1990; 10: 518-527.
58. Greider CW. Telomeres, telomerase and senescence. Bioessays 1990; 12: 363-9.
59. Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mutation Res 1991; 256: 271-282.
60. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961; 25: 585-621.
61. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992; 11: 1921-1929.
62. Sharma MC, Sokoloski JA, Perez JR, Maltese JY, Sartorelli AC, Stein CA, Nichols G, Khaled Z, Telang NT, Narayanan R. Differentiation of immortal cells inhibits telomerase acticity. Proc Natl Acad Sci USA 1995; 92: 12343-12346.
63. Holt SE, Wright WE, Shay JW. Regulation of telomerase activity in immortal cell lines. Mol Cell Biol 1996; 16: 2932-2939.
64. Savoysky E, Yoshida K, Ohtomo T, Yamaguchi Y, Akamatsu K, Yamazaki T, Yoshida S, Tsuchiya M. Down-regulation of telomerase activity is an early event in the differentiation of HL60 cells. Biochem Biophys Res Commun 1996; 226: 329-334.
65. Shay JW, Wright WE. The reactivation of telomerase activity in cancer progression. Trends in Genetics 1996; 12: 129-131.
66. Shay JW, Werbin H, Wright WE. Telomeres and telomerase in human leukemias. Leukemia 1996; 10: 1255-1261.
67. Greaves M. Is telomerase activity in cancer due to selection of stem cells and differentiation arrest? Trends in Genetics 1996; 12: 127-128.
68. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA 1995; 92: 9082-9086.
69. Counter CM, Gupta J, Harley CB, Leber B, Bacchettt S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995; 85: 2315-2320.
70. Hiyama K, Hirai Y, Kyoizumi S, Akiyama M, Hiyama E, Piatyszek MA, Shay JW, Ishioka S, Yamakido M. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 1995; 155: 3711-3715.
71. Bodnar AG, Kim NW, Effros RB, Chiu CP. Mechanism of telomerase induction during T cell activation. Exp Cell Res 1996; 228: 58-64.
72. Igarashi H, Sakaguchi N. Telomerase activity is induced by the stimulation to antigen receptor in human peripheral lymphocytes. Biochem Biophys Res Commun 1996; 219: 649-655.
73. Igarashi H, Sakaguchi N. Telomerase activity is induced in human peripheral B lymphocytes by the stimulation to antigen receptor. Blood 1997; 89: 1299-1307.
74. Weng NP, Levine BL, June CH, Hodes RJ. Regulated expression of telomerase activity in human T lymphocyte development and activation. J Exper Med 1996; 183: 2471-2479.
75. Taylor RS, Ramirez RD, Ogoshi M, Chaffins M, Piatyszek MA, Shay JW. Detection of telomerase activity in malignant and nonmalignant skin conditions. J Invest Dermatol 1996; 106: 759-765.
76. Hrle-Bachor C, Boukamp P. Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin keratinocytes. Proc Natl Acad Sci USA 1996; 93: 6476-6481.
77. Hiyama E, Hiyama K, Tatsumoto N, Shay JW, Yokoyama T. Telomerase activity in human intestine. Int J Oncol 1996; 9: 453-458.
78. Ramirez RD, Wright WE, Shay JW, Taylor RS. Telomerase activity concentrates in the mitotically active segments of human hair follicles. J Invest Dermatol 1997; 108: 113-117.
79. Brien TP, Kallakury BV, Lowry CV, Ambros RA, Muraca PJ, Malfetano JH, Ross JS. Telomerase activity in benign endometrium and endometrial carcinoma. Cancer Res 1997; 57: 2760-2764.
80. Kyo S, Takakura M, Kohama T, Inoue M. Telomerase activity in human endometrium. Cancer Res 1997; 57: 610-614.
81. Saito T, Schneider A, Martel N, Mizumoto H, Bulgay-Moerschel M, Kudo R, Nakazawa H. Proliferation-associated regulation of telomerase activity in human endometrium and its potential implication in early cancer diagnosis. Biochem Biophys Res Commun 1997; 231: 610-614.
82. Shroyer KR, Stephens JK, Silverberg SG, Markham N, Shroyer AL, Wilson ML, Enomoto T. Telomerase expression in normal endometrium, endometrial hyperplasia, and endometrial adenocarcinoma. Int J Gynecol Pathol 1997; 16: 225-232.
83. Bonatz G, Klapper W, Barthe A, Heidorn K, Jonat W, Krupp G, Parwaresch R. Analysis of telomerase expression and proliferative activity in the different layers of cyclic endometrium. Biochem Biophys Res Commun 1998; 253: 214-221.
84. Klapper W, Singh KK, Heidorn K, Parwaresch R, Krupp G. Regulation of telomerase activity in quiescent immortalized human cells. Biochim Biophys Acta 1998; 1442: 120-126.
85. Bonatz G, Frahm SO, Klapper W, Helfenstein A, Heidorn K, Jonat W, Rudolph P, Krupp G, Parwaresch R. High telomerase activity is associated with cell cycle deregulation and rapid progression in endometrioid carcinoma of the uterus. 1999; submitted for publication.
86. Gerdes J, Dallenbach F, Lennert K, Lemke H, Stein H. Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol 1984; 2: 365-371.
87. Greider CW. Telomerase activity, cell proliferation, and cancer. Proc Natl Acad Sci USA 1998; 95: 90-92.
88. Kreipe H, Wacker HH, Heidebrecht HJ, Haas K, Hauberg M, Tiemann M, Parwaresch R. Determination of the growth fraction in non-Hodgkin's lymphomas by monoclonal antibody Ki-S5 directed against a formalin-resistant epitope of the Ki-67 antigen. Am J Pathol 1993; 142: 1689-1694.
89. Holt SE, Aisner DL, Shay JW, Wright WE. Lack of cell cycle regulation of telomerase activity in human cells. Proc Natl Acad Sci USA 1997; 94: 10687-10692.
90. Belair CD, Yeager TR, Lopez PM, Reznikoff CA. Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc Natl Acad Sci USA 1997; 94: 13677-13682.
91. Bonatz G, Luttges J, Hedderich J, Inform D, Jonat W, Rudolph P, Parwaresch R. Prognostic significance of a novel proliferation marker, anti-repp 86, for endometrial carcinoma: a multivariate study. Hum Pathol 1999; 30: 949-956.
92. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 1996; 18: 173-179.
93. Tahara H, Nakanishi T, Kitamoto M, Nakashio R, Shay JW, Tahara E, Kajiyama G, Ide T. Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res 1995; 55: 2734-2736.
94. Kojima H, Yokosuka O, Imazeki F, Saisho H, Omata M. Telomerase activity and telomere length in hepatocellular carcinoma and chronic liver disease. Gastroenterology 1997; 112: 493-500.
95. Prowse KR, Avilion AA, Greider CW. Identification of a nonprocessive telomerase activity from mouse cells. Proc Natl Acad Sci USA 1993; 90: 1493-1497.
96. Prowse KR, Greider CW. Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc Natl Acad Sci USA 1995; 92: 4818-4822.
97. Blasco MA, Funk W, Villeponteau B, Greider CW. Functional characterization and developmental regulation of mouse telomerase RNA. Science 1995; 269: 1267-1270.
98. Fitzgerald MS, McKnight TD, Shippen DE. Characterization and developmental patterns of telomerase expression in plants. Proc Natl Acad Sci USA 1996; 93: 14422-14427.
99. Heller K, Kilian A, Piatyszek MA, Kleinhofs A. Telomerase activity in plant extracts. Mol Gen Genet 1996; 252: 342-345.
100. Krupp G, Khne K, Tamm S, Klapper W, Heidorn K, Rott A, Parwaresch R. Molecular basis of artifacts in the detection of telomerase activity and a modified primer for a more robust, TRAP' assay. Nucleic Acids Res 1997; 25: 919-921.
101. Klapper W, Heidorn K, Khne K, Parwaresch R, Krupp G Telomerase activity in 'immortal' fish. FEBS Lett 1998; 434: 409-412.
102. Ortego LS, Hawkins WE, Walker WW, Krol RM, Benson WH. Detection of proliferating cell nuclear antigen in tissues of three small fish species. Biotechnic & Histochem 1994; 69: 317-323.
103. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nature Medicine 1995; 1: 249-255.
104. Langford LA, Piatyszek MA, Xu R, Schold Jr SC, Shay JW. Telomerase activity in human brain tumors. Lancet 1995; 346: 1267-1268.
105. Langford LA, Piatyszek MA, Xu R, Schold SC Jr, Wright WE, Shay JW. Telomerase activity in ordinary meningiomas predicts poor outcome. Hum Pathol 1997; 28: 416-420.
106. Nakatani K, Yoshimi N, Mori H, Yoshimura S, Sakai H, Shinoda J, Sakai N. The significant role of telomerase activity in human brain tumors. Cancer 1997; 80: 471-176.
107. Hiyama E, Hiyama K, Ohtsu K, Yamaoka H, Ichikawa T, Shay JW, Yokoyama T. Telomerase activity in neuroblastoma: is it a prognostic indicator of clinical behaviour? Eur J Cancer 1997; 33: 1932-1936.
108. Zhang W, Piatyszek MA, Kobayashi T, Estey E, Andreeff M, Deisseroth AB, Wright WE, Shay JW. Telomerase activity in human acute myelogenous leukemia: inhibition of telomerase activity by differentiation-inducing agents. Clinical Cancer Res 1996; 2: 799-803.
109. Oyashiki JH, Oyashiki K, Iwama H. Clinical implications of telomerase activity levels in acute leukemia. Clinical Cancer Res 1997; 3: 619-625.
110. Hiyama E, Gollahon L, Kataoka T, Kuroi K, Yokoyama T, Gazdar AF, Hiyama K, Piatyszek MA, Shay JW. Telomerase activity in human breast tumors. J Natl Cancer Inst 1996; 88: 116-122.
111. Clark GM, Osborne CK, Levitt D, Wu F, Kim NW. Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst 1997; 89: 1874-1881.
112. Hoos A, Hepp HH, Kaul S, Ahlert T, Basiert G, Wallwiener D. Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer. Int J Cancer 1998; 79: 8-12.
113. Glaessl A, Bosserhoff AK, Buettner R, Hohenleutner U, Landthaler M, Stolz W. Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas. Arch Dermatol Res 1999; 291: 81-87.
114. Rudolph P, Schubert C, Tamm S, Heidorn K, Hauschild A, Michalska I, Majewski S, Krupp G, Jablonska S, Parwaresch R. Telomerase activity in melanocytic lesions - a potential marker of tumor biology. Am J Pathol 2000; 156: 1425-1437.
115. Tahara H, Kuniyasu H, Yokozaki H, Yasui W, Shay JW, Ide T, Tahara E. Telomerase activity in preneoplastic and neoplastic gastric and colorectal lesions. Clin Cancer Res 1995; 1: 1245-1251.
116. Hiyama E, Yokoyama T, Tatsumoto N, Hiyama K, Imamura Y, Murakami Y, Kodama T, Piatyszek MA, Shay JW, Matsuura Y. Telomerase activity in gastric cancer. Cancer Res 1995; 55: 3258-3262.
117. Ahn MJ, Non YH, Lee YS, Lee JH, Chung TJ, Kim IS, Choi IY, Kim SH, Lee JS, Lee KH. Telomerase activity and its clinicopathological significance in gastric cancer. Eur J Cancer 1997; 33: 1309-1313.
118. Urquidi V, Tarin D, Goodison S. Telomerase in cancer: clinical applications. Ann Med 1998; 30: 419-430.
119. Shay JW. Telomerase in cancer: diagnostic, prognostic, and therapeutic implications. Cancer J Sci Am 4 Suppl 1998; 1: S26-S34.
120. McKenzie KE, Umbricht CB, Sukumar S. Applications of telomerase research in the fight against cancer. Mol Med Today 1999; 5: 114-122.
121. 2 and M. Blood 1997; 90: 226-233.
122. Bacchetti S, Wynford-Thomas D (guest editors). Special issue: telomeres and telomerase in cancer. Eur J Cancer 1997; 33: 703-800.
123. Olovnikov AM (guest editor). Special issue: telomere, telomerase, cancer and aging. Biochemistry (Moscow) 1997; 62: 1179-1338.
124. Rudolph P, Knchel R, Endl E, Heidebrecht HJ, Hofstdter F, Parwaresch R. The immunohistochemical marker Ki-S2: cell cycle kinetics and tissue distribution of a novel proliferation-specific antigen. Mod. Pathol. 1998; 11: 450-456.
125. Iwao T, Hiyama E, Yokoyama T, Tsuchida A, Hiyama K, Murakami Y, Shimamoto F, Shay JW, Kajiyama G. Telomerase activity for the preoperative diagnosis of pancreatic cancer. J Natl Cancer Inst 1997; 89: 1621-1623.
126. Duggan BD, Wan M, Yu MC, Roman LD, Muderspach LI, Delgadillo E, Li WZ, Martin SE, Dubeau L. Detection of ovarian cancer cells: comparison of a telomerase assay and cytologic examination. J Natl Cancer Inst 1998; 90: 238-242.
127. Sawant SG, Gregoire V, Dhar S, Umbricht CB, Cvilic S, Sukumar S, Pandita TK. Telomerase activity as a measure for monitoring radiocurability of tumor cells. FASEB J 1999; 13: 1047-1054.
128. Ohyashiki K, Yahata N, Iwama H, Aizawa T, Miki M. [Telomerase activity and determination of cancer in urological neoplasias using exfoliated urinary cells: in situ TRAP assay and its application]. Nippon Rinsho 1998; 56: 1299-303.
129. Wright WE, Shay JW, Piatyszek MA. Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res 1995; 23: 3794-3795.
130. Kim NW, Wu F. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res 1997; 25: 2595-2597.
131. Yan P, Bosman FT, Benhattar J. Tissue quality is an important determinant of telomerase activity as measured by TRAP assay. BioTechniques 1998; 25: 660-662.
132. Norrback KF, Enblad G, Erlanson M, Sundstrom C, Roos G. Telomerase activity in Hodgkin's disease. Blood 1998; 92: 567-573.
133. Klapper W, Hanne A, Heidorn K, Parwaresch R, Krupp G. TRAP assay - technical aspects: detect and inhibit RNases in lysates. Cold Spring Harbor Meeting on Telomeres & Telomerase, 1999: p. 72.
134. Ohyashiki K, Ohyashiki JH, Nishimaki J, Toyama K, Ebihara Y, Kato H, Wright WE, Shay JW. Cytological detection of telomerase activity using an in situ telomeric repeat amplification protocol assay. Cancer Res 1997; 57: 2100-2103.
135. Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 1998; 58: 4168-4172.
136. Liu K, Schoonmaker MM, Levine BL, June CH, Hodes RJ, Weng N. Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. Proc Natl Acad Sci USA 1999; 96: 5147-5152.
137. Ramakrishnan S, Eppenberger U, Mueller H, Shinkai Y, Narayanan R. Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res 1998; 58: 622-625.
138. Li H, Zhao LL, Funder JW, Liu JP. Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells. J Biol Chem 1997; 272: 16729-16732.
139. Li H, Zhao L, Yang Z, Funder JW, Liu JP. Telomerase is controlled by protein kinase Calpha in human breast cancer cells. J Biol Chem 1998; 273: 33436-33442.
140. Kang SS, Kwon T, Kwon DY, Do SI. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 1999; 274: 13085-13090.
141. Tahara H, Yasui W, Yahara E, Fujimoto J, Ito K, Tamai K, Nakayama J, Ishikawa F, Ide T. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 1999; 18: 1561-1567.
142. Bacchetti S. Telomere maintenance in tumour cells. Cancer Surv 1996; 28: 197-216.
143. Shiels PG, Kind AJ, Campbell KH, Waddington D, Wilmut I, Colman A, Schnieke AE. Analysis of telomere lengths in cloned sheep. Nature 1999; 399: 316-317.
144. Lundblad V, Blackburn EH. An alternative pathway for yeast telomere maintenance rescues est1- senescence. Cell 1993; 73: 347-360.
145. Murnane JP, Sabatier L, Marder BA, Morgan WF. Telomere dynamics in an immortal human cell line. EMBO J 1994; 13: 4953-4962.
146. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal cells without detectable telomerase activity. EMBO J 1995; 14: 4240-4248.
147. Bryan TM, Reddel RR. Telomere dynamics and telomerase activity in in vitro immortalised human cells. Eur J Cancer 1997; 33: 767-773.
148. Norton JC, Piatyszek MA, Wright WE, Shay JW, Corey DR. Inhibition of human telomerase by peptide nucleic acids. Nature Biotech 1996; 14: 615-619.
149. Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA, Greider CW. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997; 91: 25-34.
150. Lee HW, Blasco MA, Gottlieb GJ, Horner JWII, DePinho RA. Essential role of mouse telomerase in highly proliferative organs. Nature 1998; 392: 569-574.
151. Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 1996; 16: 53-65.
152. Yegorov YE, Chernov DN, Akimov SS, Akhmalisheva AK, Smirnova YB, Shinkarev DB, Semenova IV, Yegorova IN, Zelenin AV. Blockade of telomerase function by nucleoside analogs. Biochemistry (Mosc) 1997; 62: 1296-305.
153. Pai RB, Pai B, Kukhanova M, Dutschmann GE, Guo X, Cheng YC. Telomerase from human leukemia cells: properties and its interaction with deoxynucleotide analogues. Cancer Res 1998; 58: 1909-1913.
154. Melana SM, Holland JF, Pogo BG. Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3'-azido-3'-deoxythymidine. Clin Cancer Res 1998; 4: 693-696.
155. Ishibashi T, Lippard SJ. Telomere loss in cells treated with cisplatin. Proc Natl Acad Sci USA 1998; 95: 4219-4223.
156. Naasani I, Seimiya H, Tsuruo T. Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochem Biophys Res Commun 1998; 249: 391-396.
157. Nakane H, Ono K. Differential inhibitory effects of some catechin derivatives on the activities of human immunodeficiency virus reverse transcriptase and cellular deoxyribonucleic and ribonucleic acid polymerases. Biochemistry 1990; 29: 2841-2845.
158. Pitts AE, Corey DR. Inhibition of human telomerase by 2'-O-methyl-RNA. Proc Natl Acad Sci USA 1998; 95: 11549-11554.
159. Mata JE, Joshi SS, Palen B, Pirruccello SJ, Jackson JD, Elias N, Page TJ, Medlin KL, Iversen, PL. A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo. Toxicol Appl Pharmacol 1997; 144: 189-197.
160. Matthes E, Lehmann C. Telomerase protein rather than its RNA is the target of phosphorothioate-modified oligonucleotides. Nucleic Acids Res 1999; 27: 1152-1158.
161. Wan MSK, Fell PL, Akhtar S. Synthetic 2'-O-methyl-modified hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibitors of telomerase activity. Antisense and Nucleic Acid Drug Dev 1998; 8: 309-317.
162. Yokoyama Y, Takahashi Y, Shinohara A, Lian Z, Wan X, Niwa K, Tamaya T. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res 1998; 58: 5406-5410.
163. Hamilton SE, Pitts AE, Katipally RR, Jia X, Rutter JP, Davies BA, Shay JW, Wright WE, Corey DR. Identification of determinants for inhibitor binding within the RNA active site of human telomerase using PNA scanning. Biochemistry 1997; 36: 11873-11880.
164. Hamilton SE, Simmons CG, Kathiriya IS, Corey DR. Cellular delivery of peptide nucleic acids and inhibition of human telomerase. Chemistry & Biology 1999; 6: 343-351.
165. Fletcher TM, Salazar M, Chen SF. Human telomerase inhibition by 7-deaza-2'-deoxypurine nucleoside triphosphates. Biochemistry 1996; 35: 15611-15617.
166. Pandit B, Bhattacharyya NP. Detection of telomerase activity in Chinese hamster V79 cells and its inhibition by 7-deaza-deoxy guanosine triphosphate and (TTAGGG)4 in vitro. Biochem Biophys Res Commun 1998; 251: 620-624.
167. Togashi K, Kakeya H, Morishita M, Song YX, Osada H. Inhibition of human telomerase activity by alterperylenol. Oncol Res 1998; 10: 449-453.
168. Fedoroff OY, Salazar M, Han H, Chemeris VV, Kerwin SM, Hurley LH NMR-Based model of a telomerase inhibiting compound bound to G- quadruplex DNA. Biochemistry 1998; 37: 12367-12374.
169. Perry PJ, Reszka AP, Wood AA, Read MA, Gowan SM, Dosanjh HS, Trent JO, Jenkins TC, Kelland LR, Neidle S. Human telomerase inhibition by regioisomeric disubstituted amidoanthracene-9,10-diones. J Med Chem 1998; 41: 4873-4884.
170. Fu W, Begley JG, Killen MW, Mattson MP. Anti-apoptotic role of telomerase in pheochromocytoma cells. J Biol Chem 1999; 274: 7264-7271.
171. Gaeta FCA, Galan AA, Stracker EC. Telomerase inhibitors. United States Patent 1997; 5703116.
172. Sogawa K, Sumida T, Hamakawa H, Yamada T, Matsumoto K, Matsuda M, Oda H, Miyake H, Tashiro S, Okutani K. Inhibitory effect of a marine microalgal polysaccharide on the telomerase activity in K562 cells. Res Commun Mol Pathol Pharmacol 1998; 99: 259-265.
173. Hogan Jr JC. Directed combinatorial chemistry. Nature SUPP 1996; 384: 17-19.
174. Runge KW, Zakian VA. Introduction of extra telomeric DNA sequences into Saccharomyces cerevisiae results in telomere elongation. Mol Cell Biol 1989; 9: 1488-1497.
175. Wright WE, Brasiskyte D, Piatyszek MA, Shay JW. Experimental elongation of telomeres extends the lifespan of immortal x normal cell hybrids. EMBO J 1996; 15: 1734-1741.
176. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279: 349-352.
177. Morales CP, Holt SE, Ouellette M, Kaur KJ, Van Y, Wilson KS, White MA, Wright WE, Shay JW. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nature Genetics 1999; 21: 115-118.
178. Jiang XR, Jimenez G, Chang E, Frolkis M, Kusler B, Sage M, Beeche M, Bodnar AG, Wahl GM, Tlsty TD, Chiu CP. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nature Genetics 1999; 21: 111-114.
179. Rubin H. Telomerase and cellular lifespan: ending the debate? Nature Biotech 1998; 16: 396-397.
180. Kiyono T, Foster SA, Kooter JM, McDougall JK, Galloway DA, Klingelhutz AJ. Both Rb/p16(INK4a) inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998; 396: 84-88.
181. Wei S, Sedivy JM. Expression of catalytically active telomerase does not prevent premature senescence caused by overexpression of oncogenic Ha-Ras in normal human fibroblasts. Cancer Res 1999; 59: 1539-1543.
182. Ouellette MM, Aisner DL, Savre-Train I, Wright WE, Shay JW. Telomerase activity does not always imply telomere maintenance. Biochem Biophys Res Commun 1999; 254: 795-803.
183. Wynn RF, Cross MA, Hatton C, Will AM, Lashford LS, Dexter TM, Testa NG. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet 1998; 351: 178-181.
184. Akiyama M, Hoshi Y, Sakurai S, Yamada H, Yamada O, Mizoguchi H. Changes of telomere length in children after hematopoietic stem cell transplantation. Bone Marrow Transplant 1998; 21: 167-171.
185. Frenck RW Jr, Blackburn EH, Shannon KM. The rate of telomere sequence loss in human leukocytes varies with age. Proc Natl Acad Sci USA 1998; 95: 5607-5610.
186. Zeichner SL, Palumbo P, Feng Y, Xiao X, Gee D, Sleasman J, Goodenow M, Biggar R, Dimitrov D. Rapid telomere shortening in children. Blood 1999; 93: 2824-2830.
187. Hornsby PJ. The new science and medicine of cell transplantation. ASM News 1999; 65: 208-214.
188. Ferber D. Lab-grown organs begin to take shape. Science 1999; 284: 422-425.
189. Faragher RG, Jones CJ, Kipling D. Telomerase and cellular lifespan: ending the debate? Nature Biotech 1998; 16: 701-702.
190. Rubin H. Resolving contradictory reports on cell aging. Nature Biotech 1999; 17: 4.
191. Kipling D, Faragher RG. Telomeres. Ageing hard or hardly ageing? Nature 1999; 398: 191-193.
192. Kipling D, Wynford-Thomas D, Jones CJ, Akbar A, Aspinall R, Bacchetti S, Blasco MA, Broccoli D, DePinho RA, Edwards DR, Effros RB, Harley CB, Lansdorp PM, Linskens MH, Prowse KR, Newbold RF, Olovnikov AM, Parkinson EK, Pawelec G, Ponten J, Shall S, Zijlmans M, Faragher RG. Telomere-dependent senescence. Nature Biotech 1999; 17: 313-314.
193. Hsin H, Kenyon C. Signals from the reproductive system regulate the lifespan of C. elegans. Nature 1999; 399: 362-366.
194. Greenberg RA, O'Hagan RC, Deng H, Xiao Q, Hann SR, Adams RR, Lichtsteiner S, Chin L, Morin GB, DePinho RA. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 1999; 18: 1219-1226.
195. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J, Dalla-Favera R. Direct activation of TERT transcription by c-Myc. Nature Genet 1999; 21: 220-224.
196. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 1999; 3: 565-577.
197. Norrback KF, Roos G. Telomeres and telomerase in normal and malignant haematopoietic cells. Eur J Cancer 1997; 33: 774-780.
198. Nugent CI, Bosco G, Ross LO, Evans SK, Salinger AP, Moore JK, Haber JE, Lundblad V. Telomere maintenance is dependent on activities required for end repair of double-strand breaks. Curr Biol 1998; 8: 657-660.
199. Yu GL, Bradley JD, Attardi LD, Blackburn EH. In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena-telomerase RNAs. Nature 1990; 344: 126-132.
200. McEachern MJ, Blackburn EH. Runaway telomere elongation caused by telomerase RNA gene mutations. Nature 1995; 376: 403-409.
201. Takahashi H, Fujiwara H. Transcription analysis of the telomeric repeat-specific retrotransposons TRAS1 and SART1 of the silkworm Bombyx mori. Nucleic Acids Res 1999; 27: 2015-2021.
202. Klapper W, Heidorn K, Khne K, Parwaresch R, Krupp G. 1999; unpublished observation.
203. de Lange T, Jacks T. For better or worse? Telomerase inhibition and cancer. Cell 1999; 98: 273-275.
204. Rudolph KL, Chang S, Lee HW, Blasco M, Gottlieb GJ, Greider C, DePinho RA. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 1999; 96: 701-712.
205. Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ, Greider CW, DePinho RA. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999; 97: 527-538.
206. Gandhi L, Collins K. Interaction of recombinant Tetrahymena telomerase proteins p80 and p95 with telomerase RNA and telomeric DNA substrates. Genes & Dev 1998; 12: 721-733.
207. Hammond PW, Lively TN, Cech TR. The anchor site of telomerase from Euplotes aediculatus revealed by photo-cross-linking to single- and double-stranded DNA primers. Mol Cell Biol 1997; 17: 296-308.
208. McClintock B. The stability of broken ends of chromosomes in Zea mays. Genetics 1941; 26: 234-282.
209. Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, Meyne J, Ratliff RL, Wu JR. A highly conserved repetitive DNA sequence (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci USA 1988; 85: 6622-6626.
210. Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB, Greider CW, Harley CB. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci USA 1992; 89: 10114-10118.
211. Vaziri H, Schachter F, Uchida I, Wei L, Zhu X, Effros R, Cohen D, Harley CB. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. Am J Hum Genet 1993; 52: 661-667.
212. Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci USA 1994; 91: 9857-9860.
213. Chong L, Steensel Bv, Broccoli D, Erdjument-Bromage H, Hanish J. Tempst P, de Lange T. A human telomeric protein. Science 1995; 270: 1663-1667.
214. Counter CM, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber DA, Weinberg RA. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 1998; 16: 1217-1222.
215. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H, Nakanishi T, Ide T, Ishikawa F. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nature Genet 1998; 18: 65-68.
216. Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 1998; 8: 279-282.
217. Cong YS, Wen J, Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 1999; 8: 137-142.
218. Wick M, Zubov D, Hagen G. Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene 1999; 232: 97-106.
219. Horikawa I, Cable PL, Afshari C, Barrett JC. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 1999; 59: 826-830.
220. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, Inoue M. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 1999; 59: 551-557.
221. Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ, Greider CW, DePinho RA. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999; 97: 527-538.
222. Rudolph P, Alm P, Heidebrecht HJ, Bolte H, Ratjen V, Baldetorp B, Ferno M, Olsson H, Parwaresch R. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. J Natl Cancer Inst 1999; 91: 271-278.
223. Krupp G, Klapper W, Parwaresch R. Cell proliferation, carcinogenesis and diverse mechanisms of telomerase regulation. Cell Moll Life Sci 2000; 57: 464-486.
224. Lanza RP, Cibelli JB, Blackwell C, Cristofalo VJ, Francis MK, Bearlocher GM, Mak J, Schertzer M, Chavaz EA, Sawyer N, Lansdorp PM, West MD. Extension of cell life-span and telemore length in animals cloned from senescent somatic cells. Science 2000; 288: 665-659.